CAR-T cell therapy represents a major breakthrough in the treatment of hematological malignancies, including multiple myeloma, non-Hodgkin lymphoma (NHL), and acute lymphoblastic leukemia (ALL). However, there are several toxicities associated with these agents, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections.
In this podcast, you will hear from experts Eleni Gavriilaki, MD, PhD, G. Papanikolaou Hospital, Thessaloniki, Greece, Kevin McNerney, MD, MSc, Johns Hopkins All Children’s Hospital, St. Petersburg, FL, and Andriyana Bankova, MD, University Hospital Zurich, Zurich, Switzerland, who share some insights into the treatment and management of these common toxicities.
Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs
EHA 2021: targeted therapies for ALL
Texas MPN Workshop 2021: updates on interferons for MPNs
EHA 2021: real-world data on myeloma, lymphoma and CLL
Novel BTK inhibitors for NHL
Latest updates on T-cell therapies for non-Hodgkin lymphoma
Novel CD20/CD3 bispecific antibodies in NHL
Latest updates on CAR-T therapy for lymphoma
EHA & ICML 2021: updates in Hodgkin lymphoma
Latest transplant updates from EHA 2021
Key updates on CAR-T therapy for multiple myeloma
The Lymphoma Sessions: highlights from EHA and ICML 2021
The CLL Sessions: highlights from EHA and ICML 2021
EHA 2021: updates on treatment for MDS
iwNHL 2021: immunotherapy and the microenvironment
The Myeloma Sessions: highlights from EHA and ASCO 2021
EHA 2021: key trial updates in myelofibrosis
The MPN Sessions: highlights from EHA and ASCO 2021
The MDS Sessions: highlights from ASCO/EHA 2021
EHA 2021: fixed-duration therapies and sequencing in CLL
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive